{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:22:06Z","timestamp":1761578526714},"reference-count":69,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,1,21]],"date-time":"2008-01-21T00:00:00Z","timestamp":1200873600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Defined by isolated del 5q and no excess of marrow blasts, the \u20185q\u2010 syndrome\u2019 is a specific type of myelodysplastic syndrome (MDS) with particular characteristics, including severe anaemia, frequent thrombocytosis, typical dysmegakaryopoiesis and favourable outcome. Its pathogenesis remains uncertain, particularly regarding the role of the inactivation of gene(s) situated in 5q. Until the advent of lenalidomide, repeated red blood cell (RBC) transfusions were generally the only treatment for 5q\u2010 syndrome, which was resistant to other therapeutic approaches. Lenalidomide can lead to RBC transfusion independence in at least two\u2010thirds of cases of 5q\u2010 syndrome, and about one half of those responses are maintained after 2\u2003years of treatment. Importantly, frequent complete pathological and cytogenetic responses are also obtained. Grade 3 or 4 neutropenia and thrombocytopenia, especially during the first 6\u20138\u2003weeks of treatment, are the major side effects of lenalidomide, justifying close clinical and blood counts monitoring. Preliminary results suggest that lenalidomide is also active in MDS with del 5q other than the 5q\u2010 syndrome. The mechanisms of action of lenalidomide, although uncertain, appear to include targeting of the del 5q clone. Therefore, lenalidomide may have an effect on disease course and survival, which is currently being assessed in clinical trials.<\/jats:p>","DOI":"10.1111\/j.1365-2141.2007.06910.x","type":"journal-article","created":{"date-parts":[[2008,2,6]],"date-time":"2008-02-06T07:56:06Z","timestamp":1202284566000},"page":"267-278","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["The role of lenalidomide in the management of myelodysplasia with del 5q"],"prefix":"10.1111","volume":"140","author":[{"given":"Charikleia","family":"Kelaidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginie","family":"Eclache","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Fenaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,21]]},"reference":[{"issue":"1","key":"e_1_2_8_2_1","first-page":"712a","article-title":"Is there a role for ATRA in combination to EPO in lower risk myelodysplastic syndromes? Preliminary results of a phase II study","volume":"106","author":"Ades L.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.10.2967.2967"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1323"},{"key":"e_1_2_8_5_1","first-page":"375","article-title":"Multilineage involvement in the 5q\u2010 syndrome: a fluorescent in situ hybridization study on bone marrow smears","volume":"86","author":"Bigoni R.","year":"2001","journal-title":"Haematologica"},{"key":"e_1_2_8_6_1","first-page":"69","article-title":"Molecular pathogenesis of the myelodysplastic syndromes, including the 5q\u2010 syndrome","volume":"2","author":"Boultwood J.","year":"2006","journal-title":"Hematology (EHA Educ Program)"},{"key":"e_1_2_8_7_1","doi-asserted-by":"crossref","first-page":"3253","DOI":"10.1182\/blood.V84.10.3253.3253","article-title":"The 5q\u2010syndrome","volume":"84","author":"Boultwood J.","year":"1994","journal-title":"Blood"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4638"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05817.x"},{"issue":"1","key":"e_1_2_8_10_1","doi-asserted-by":"crossref","first-page":"372a","DOI":"10.1182\/blood.V106.11.372.372","article-title":"Anti\u2010angiogenic in vivo effect of lenalidomide (CC\u20105013) in myelodysplastic syndrome with del(5q) chromosome abnormality and its relation to the course of disease","volume":"106","author":"Buesche G.","year":"2005","journal-title":"Blood"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-07-2252"},{"key":"e_1_2_8_12_1","first-page":"3671","article-title":"Report of an international working group to standardize response criteria for myelodysplastic","volume":"96","author":"Cheson B.D.","year":"2000","journal-title":"Blood"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.13.3575"},{"key":"e_1_2_8_15_1","first-page":"865","article-title":"NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q)","volume":"89","author":"Fidler C.","year":"2004","journal-title":"Haematologica"},{"issue":"1","key":"e_1_2_8_16_1","first-page":"100","article-title":"Inhibition of cell proliferation by lenalidomide is associated with stimulation of EGR1 transcriptional activity in a chromosome 5 deleted Burkitt\u2019s lymphoma and multiple myeloma cell line","volume":"92","author":"Gandhi A.","year":"2007","journal-title":"Haematologica"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403189"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-005-1027-3"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1437"},{"issue":"1","key":"e_1_2_8_20_1","first-page":"S121","article-title":"Management of haematological adverse events in MDS patients treated with lenalidomide","volume":"31","author":"Giagounidis A.A.","year":"2007","journal-title":"Leukemia Research"},{"issue":"1","key":"e_1_2_8_21_1","first-page":"S121","article-title":"Management of non\u2010haematological adverse events in MDS patients treated with lenalidomide","volume":"31","author":"Giagounidis A.A.","year":"2007","journal-title":"Leukemia Research"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0217-y"},{"key":"e_1_2_8_23_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1177\/107327480601304s04","article-title":"Cost effectiveness of lenalidomide in the treatment of transfusion\u2010dependent myelodysplastic syndromes in the United States","volume":"13","author":"Goss T.F.","year":"2006","journal-title":"Cancer Control"},{"key":"e_1_2_8_24_1","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenbeg G.P.","year":"1997","journal-title":"Blood"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.12.3835"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.1.68.413k23_68_75"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2007.02.008"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.7.2665.bloodjournal8872665"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2124"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404215"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3872"},{"issue":"1","key":"e_1_2_8_32_1","first-page":"158a","article-title":"Treatment with erythropoietin and G\u2010CSF improves survival in MDS patients with low transfusion need","volume":"108","author":"J\u00e4dersten M.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-01-068809"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830460415"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21792"},{"issue":"1","key":"e_1_2_8_36_1","first-page":"757a","article-title":"Treatment of myelodysplastic syndromes with del 5q before the lenalidomide era: the GFM experience","volume":"108","author":"Kelaidi C.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc053530"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404526"},{"key":"e_1_2_8_39_1","first-page":"143","article-title":"Deletions of chromosome 5 in malignant myeloid disorders","volume":"15","author":"Le Beau M.M.","year":"1992","journal-title":"Cancer Surveys"},{"issue":"1","key":"e_1_2_8_40_1","first-page":"737a","article-title":"Kinesin family member 20A (KIF20A) is specifically downregulated in 5q\u2010 CD34\n                     +\n                   and CD61\n                     +\n                   cells and uniparental disomy is not feature of 5q\u2010 syndrome","volume":"108","author":"Lea N.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2007.01.013"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830490304"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0145-2126(07)70016-4"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041668"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061292"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.11.2865"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1512"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2001.02933.x"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06070.x"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V81.4.1040.1040"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404677"},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOH.0b013e328016847a"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22047"},{"key":"e_1_2_8_54_1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood.V82.3.737.737","article-title":"Treatment of anemia in myelodysplastic syndromes using recombinant human granulocyte colony\u2010stimulating factor in combination with erythropoietin","volume":"82","author":"Negrin R.S.","year":"1993","journal-title":"Blood"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.6.2012"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-079368"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6715"},{"issue":"1","key":"e_1_2_8_58_1","first-page":"158a","article-title":"Prognostic factors and response duration in 419 MDS treated with erythropoietin \u00b1 GCSF: the GFM experience","volume":"108","author":"Park S.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_8_59_1","first-page":"566","article-title":"Clinical and prognostic implications of chromosome 5q deletions: 96 high resolution studied patients","volume":"5","author":"Pedersen B.","year":"1991","journal-title":"Leukemia"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-12-4769"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0610477104"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.958"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04713.x"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402894"},{"issue":"1","key":"e_1_2_8_65_1","first-page":"756a","article-title":"Low doses of thalidomide in low risk MDS with transfusion\u2010dependent anemia: the GFM THAL\u2010SMD\u2010200 trial","volume":"108","author":"Tamburini J.","year":"2006","journal-title":"Blood"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2002.03583.x"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-4608(96)00350-0"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/251437a0"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-4608(85)90016-0"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.13.6948"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2141.2007.06910.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2141.2007.06910.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T11:24:14Z","timestamp":1697455454000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2141.2007.06910.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,21]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1111\/j.1365-2141.2007.06910.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06910.x","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,21]]},"assertion":[{"value":"2008-01-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}